Arbutus Biopharma is a publicly-traded (NASDAQ:ABUS) biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). We are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will result in a combination therapy that will transform the HBV treatment landscape and cure hepatitis B virus disease. Source
No articles found.
TransMedics is a commercial-stage medical technology company transforming organ tr...
TransMedics is a commercial-stage medical techn...
Astellas Pharma Inc. is a pharmaceutical company committed to the therapeutic fiel...
Astellas Pharma Inc. is a pharmaceutical compan...
Ra PharmaÂŽ is a clinical-stage biopharmaceutical company using a proprietary pept...
Ra PharmaÂŽ is a clinical-stage biopharmaceutic...
We are ProQR, a company on a mission to create new medicines for patients in need....
We are ProQR, a company on a mission to create ...
Edesa Biotech Inc. is a clinical-stage biopharmaceutical company founded by expert...
Edesa Biotech Inc. is a clinical-stage biopharm...
Checkpoint Therapeutics, Inc. (âCheckpointâ) is a clinical-stage, immuno-oncol...
Checkpoint Therapeutics, Inc. (âCheckpointâ...
Assembly Biosciences is advancing a new class of oral therapeutics for the treatme...
Assembly Biosciences is advancing a new class o...
Join the National Investor Network and get the latest information with your interests in mind.